(VELA) Study of BLU-222 in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Carboplatin
Related studies linked through entity extraction aliases.
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- Status
- TERMINATED
- Phase
- PHASE1
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Pathological Response After Neoadjuvant Treatment on NSCLC
- Status
- RECRUITING
- Phase
- N/A